Table 1.
Baseline characteristics of different parameter degrees in CLD patients. HC: healthy control; CHB: chronic hepatitis B; NAFLD: nonalcoholic fatty liver disease; HCC: hepatocellular carcinoma; PBC: primary biliary cholangitis; AIH: autoimmune hepatitis; BMI: body mass index; ALT: alanine aminotransferase; AST: aspartate aminotransferase; Alb: albumin; GGT: gamma-glutamyl transferase; CHOL: cholesterol; TG: triglyceride; FPG: fasting plasma glucose; UA: uric acid; TB: total bilirubin; DB: direct bilirubin; AFP: alpha fetoprotein; WBC: white blood cells; N: neutrophils; L: lymphocytes; PLT: platelet; G: stages of hepatitis activity; S: liver fibrosis stage.
| HC | CHB | NAFLD | HCC | PBC | AIH | |
|---|---|---|---|---|---|---|
| n | 12 | 24 | 18 | 13 | 16 | 27 |
| Gender (n (%)) | ||||||
| Male | 5 (41.6%) | 16 (66.7%) | 11 (61.1%) | 9 (69.2%) | 0 (00.0%) | 3 (11.1%) |
| Female | 7 (58.4%) | 8 (33.3%) | 7 (38.9%) | 4 (31.8%) | 16 (100.0%) | 24 (88.9%) |
| Age (m (IQR)) | 44.5 (33.25, 50.5) | 28 (25, 34) | 32 (24, 54) | 60 (47.5, 65.5) | 53 (46, 56.5) | 50.5 (45.25, 57.5) |
| BMI (kg/m2,) | 22.67 ± 2.23 | 21.02 ± 1.47 | 26.8 ± 2.43 | 23.78 ± 1.98 | 22.93 ± 3.43 | 23.13 ± 2.73 |
| ALT (IU/L, m (IQR)) | 19 (16, 20.5) | 210 (115, 317.5) | 148 (88, 206) | 27 (21.5, 38.5) | 78 (34.5, 118.5) | 103 (50.25, 271.5) |
| AST (IU/L, m (IQR)) | 18 (15, 21.75) | 98 (76.5, 133) | 74 (46, 79) | 35 (20.5, 53.5) | 60 (38, 88) | 110 (44.75, 298.25) |
| GGT (IU/L, m (IQR)) | 13.5 (10.75, 20.75) | 71 (29, 229.5) | 74 (50, 155) | 53 (16.5, 265) | 128 (59.5, 528) | 283.5 (83, 439.25) |
| CHOL (mmol/L, ) | 5.13 ± 1.19 | 5.56 ± 0.68 | 5.46 ± 1.17 | 5.76 ± 1.89 | 5.14 ± 0.83 | 5.05 ± 1.17 |
| TG (mmol/L, ) | 1.16 ± 0.35 | 1.21 ± 0.48 | 1.68 ± 0.9 | 1.25 ± 0.41 | 1.31 ± 0.62 | 1.66 ± 0.79 |
| FPG (mmol/L, ) | 5.63 ± 0.71 | 4.53 ± 0.45 | 5.42 ± 0.58 | 6.06 ± 0.46 | 5.1 ± 0.72 | 5.18 ± 0.52 |
| UA (μmol/L, ) | 319.5 ± 42.56 | 330.76 ± 113.57 | 496.04 ± 72.65 | 369.02 ± 106.38 | 259.4 ± 46.85 | 250.17 ± 83.29 |
| TB (mg/dL, ) | 15.3 ± 6.99 | 20.16 ± 8.34 | 23.73 ± 8.05 | 14.26 ± 1.98 | 15.62 ± 4.79 | 30.67 ± 23.31 |
| DB (mg/dL, m (IQR)) | 3.05 (2.18, 3.25) | 6.4 (5.35,9.15) | 4 (2.7, 5.4) | 2.8 (1.9, 3.65) | 1.9 (1.35, 7.4) | 8.9 (2.8, 19.55) |
| AFP (ng/mL, m (IQR)) | 3.38 (1.43, 4.82) | 8.11 (3.08, 11.04) | 2.34 (1.89, 4.75) | 79.33 (5.71, 253.3) | 1.86 (1.71, 3.125) | 3.85 (2.13, 6.44) |
| WBC () | 5.2 ± 1.18 | 5.72 ± 1.06 | 6.79 ± 1.2 | 5.5 ± 2.45 | 5.22 ± 1.53 | 4.1 ± 0.93 |
| N () | 3.1 ± 0.94 | 2.9 ± 1.06 | 3.91 ± 1.1 | 3.66 ± 2.76 | 2.82 ± 0.93 | 2.03 ± 0.67 |
| L (m (IQR)) | 1.75 (0.98, 2.38) | 2.1 (2, 2.35) | 2.5 (1.7, 2.8) | 1.2 (0.6, 2.2) | 1.6 (1.45, 2.25) | 1.35 (1, 1.88) |
| PLT () | 195.98 ± 139.56 | 192.2 ± 52.03 | 232.14 ± 81.1 | 239.4 ± 90.22 | 226 ± 33.9 | 176.5 ± 69.12 |
| Stages of hepatitis activity | ||||||
| G ≤ 1 | 12 | 0 | 1 | 2 | 1 | 0 |
| G = 2 | 0 | 9 | 15 | 9 | 7 | 4 |
| G = 3 | 0 | 7 | 2 | 2 | 8 | 17 |
| G = 4 | 0 | 8 | 0 | 0 | 0 | 6 |
| Liver fibrosis stage | ||||||
| S ≤ 1 | 12 | 12 | 9 | 2 | 4 | 2 |
| S = 2 | 0 | 9 | 6 | 3 | 5 | 11 |
| S = 3 | 0 | 2 | 2 | 5 | 4 | 9 |
| S = 4 | 0 | 1 | 1 | 4 | 3 | 5 |